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Summary
Microglia are the immune cells of the brain. Here we
show a massive infiltration of highly ramified and elon-
gated microglia within the core of amyloid plaques in
transgenic mouse models of Alzheimer’s disease
(AD). Many of these cells originate from the bone mar-
row, and the b-amyloid-40 and -42 isoforms are able to
trigger this chemoattraction. These newly recruited
cells also exhibit a specific immune reaction to both
exogenous and endogenous b-amyloid in the brain.
Creation of a new AD transgenic mouse that expresses
the thymidine kinase protein under the control of the
CD11b promoter allowed us to show that blood-
derived microglia and not their resident counterparts
have the ability to eliminate amyloid deposits by a
cell-specific phagocytic mechanism. These bone mar-
row-derived microglia are thus very efficient in re-
stricting amyloid deposits. Therapeutic strategies
aiming to improve their recruitment could potentially
lead to a new powerful tool for the elimination of toxic
senile plaques.
Introduction
Alzheimer’s disease (AD) is the most prevalent cause of
dementia in humans, and the symptoms are generally
manifested after the seventh decade of life. Unfortu-
nately, the causes of the disease remain largely un-
known, and this limits the development of therapeutic
strategies to treat the disease. It is a well-accepted
fact that deposition of aggregated b-amyloid to form
amyloid plaques (also known as senile plaques) is the
hallmark of AD. It is therefore important to study the de-
velopment of these deposits, as well as the effects they
have on their cellular environment. Many studies have
provided evidence that microglia are attracted to and
surround senile plaques both in human samples and in
rodent transgenic models that develop this disease
(Dickson et al., 1988; Haga et al., 1989; Itagaki et al.,
1989; Perlmutter et al., 1992; Sheng et al., 1997; Fraut-
schy et al., 1998; Wegiel et al., 2001, 2003, 2004; Malm
et al., 2005).
The precise role of these cells is still under debate. A
first proposal is that these microglia become activated
in the presence of b-amyloid and secrete neurotoxic
*Correspondence: serge.rivest@crchul.ulaval.camolecules, whereas they may also have a neuroprotec-
tive function by secreting neurotrophic agents and elim-
inating b-amyloid via phagocytosis. In support of the
neurotoxic hypothesis, a few in vitro studies of cultured
primary microglial cells have demonstrated that they se-
crete high levels of cytokines when stimulated with b-
amyloid peptides (Kim and de Vellis, 2005; Walker and
Lue, 2005). This has been linked to cytokine production
and neuronal death in cell cultures (Giulian et al., 1996;
Walker and Lue, 2005). Moreover, initial clinical trials in-
volving the treatment of patients with nonsteroidal anti-
inflammatory drugs (NSAIDs) prior to the onset of AD
have suggested that inhibiting the immune response re-
duces the occurrence of the disease (Stewart et al.,
1997; Anthony et al., 2000; in t’ Veld et al., 2001; Yip
et al., 2005). Microglia are also believed to be unable
to infiltrate the plaques and eliminate b-amyloid de-
posits by phagocytosis (Wegiel et al., 2001, 2003,
2004). These data have lead to the assumption that the
brain’s resident macrophages promote the develop-
ment of the disease, since they produce cytotoxic ele-
ments and are unable to clear the b-amyloid deposits.
On the other hand, many studies support the idea that
microglia are beneficial to the diseased brain. Indeed,
activated microglia are known to favor the release of
many neurotrophic molecules that have clear beneficial
properties for CNS elements, including neurons and ol-
igodendrocytes (Nguyen et al., 2002). In this regard, mi-
croglia inhibition causes extensive damage in acute
models of neurotoxicity (Turrin and Rivest, 2006). In ad-
dition, it has been demonstrated that an immune re-
sponse in the CNS reduces amyloid deposition (Rogers
et al., 2002; Malm et al., 2005). Some also argue that
NSAIDs have no effect in patients suspected to have al-
ready developed AD (Aisen et al., 2003) and that treat-
ment with a cyclooxygenase-2 inhibitor increases the
amount of b-amyloid found in the brain (Kukar et al.,
2005). Moreover, the notion that microglia are able to
phagocytose amyloid deposits has been supported in
previous reports (Rogers and Lue, 2001; Rogers et al.,
2002; Liu et al., 2005). It is thus crucial to further elabo-
rate the role of microglia in the etiology of AD.
We and others have recently demonstrated that bone
marrow-derived cells are able to cross the blood-brain
barrier (BBB) and differentiate into fully functional micro-
glia (Hess et al., 2004; Simard and Rivest, 2004a; Malm
et al., 2005). We also demonstrated that newly differen-
tiated blood-derived microglia express higher levels of
proteins that are required for antigen presentation and
may thus be more efficient phagocytes than resident mi-
croglia (Simard and Rivest, 2004a). In light of this, we ex-
amined the origin of microglial cells that are associated
with senile plaques in a rodent transgenic animal that
harbors a mutant human presenilin 1 and a chimeric
mouse/human b-amyloid precursor protein (APPSwe).
These animals develop amyloid deposits similar to
those found in brains of humans diagnosed with AD.
We found that a large portion of the plaque-associated
microglia were of blood origin. These cells are specifi-
cally attracted to b-amyloid-40/42, the most prevalent
Neuron
490Figure 1. Microglial Cells Infiltrate Amyloid
Plaques in APPSwe and APPSwe/PS1 Trans-
genic Animals
(A) Microglial cells in brain tissue sections
taken from APPSwe mice were stained with
an anti-iba1 antibody and peroxidase-conju-
gated secondary antibody, which were then
developed with DAB solution (brown elon-
gated cells). Tissues were also stained with
thionine. Note the particular ring formation
of microglial cells surrounding the amyloid
core (blue staining in the center of microglial
ring). (B) To compare amyloid plaques and
microglial cell localization between the
APPSwe (15-month-old) and APPSwe/PS1 (9-
month-old) transgenic animals, tissue sec-
tions were stained with Congo red or with
an anti-b-amyloid-42 antibody to reveal am-
yloid plaques (red), DAPI to visualize cell nu-
clei (blue), and anti-iba1 primary antibody/
Alexa 488-conjugated secondary antibody
to reveal microglial cells (green). Note that mi-
croglial cells surround and their projections
infiltrate senile plaques in both transgenic
models for AD. Scale bars represent 50 mm.and toxic b-amyloid isoforms found in the human brain.
We also show that these animals do not respond to
this protein with a classical innate immune response fre-
quently observed in acute models of neurotoxicity. More
importantly, we demonstrate that bone marrow-derived
microglia eliminate amyloid deposits, since transgenic
animals that specifically fail to recruit these cells to the
CNS had more plaques than their control littermates. Ac-
cording to our results, bone marrow-derived microglia
reduce the amyloid deposits via phagocytosis of
b-amyloid and thus play a critical role by restricting AD
progression. These findings present important informa-
tion that could lead to the development of a new and
effective therapy for the treatment of this devastating
disease.
Results
Microglial Cells Infiltrate Amyloid Deposits in Rodent
Models of AD
It is known that many microglial cells surround senile
plaques in humans (Dickson et al., 1988; Haga et al.,
1989; Itagaki et al., 1989) and in rodent transgenic ani-
mals that develop amyloid deposits (Perlmutter et al.,
1992; Sheng et al., 1997; Frautschy et al., 1998; Wegiel
et al., 2001, 2003). In order to test whether similar resultswould be obtained in the double-mutant transgenic line
used in this study, we compared the localization of mi-
croglia near senile plaques from the APPSwe/PS1 mutant
transgenic line with those of the more characterized
APPSwe single-mutant line. As shown in Figure 1, amy-
loid plaques are completely surrounded by microglial
cells in both transgenic lines, demonstrating that both
models share the same characteristics. Interestingly,
we have observed that ramifications of microglial cells
appear to infiltrate the core of amyloid plaques (see Fig-
ure 1 and Movie S1). There seems to be a chemoattrac-
tant gradient from the center of the plaques, and this
phenomenon was not necessarily dependent on the vol-
ume or the location of the plaques. Although both mouse
lines exhibited a tight association between b-amyloid
and microglia, APPSwe single-mutant mice take 12–15
months to develop plaques, while this process is much
faster in the brain of APPSwe/PS1 mutant mice (see be-
low).
Age-Related Migration of Blood-Derived Cells toward
Amyloid Plaques
A recent study suggests that resident microglia are less
immunocompetent than their blood-derived counter-
parts (Simard and Rivest, 2004a). Based on these results
and the fact that highly ramified and elongated microglia
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491penetrate the core of the plaques, we tested whether
these cells were resident or blood-derived microglia.
To this end, we irradiated 2-month-old APPSwe/PS1 mu-
tant transgenic mice and transplanted GFP-expressing
bone marrow cells into their blood streams. We then
sacrificed the animals 2–7 months later and observed
brain tissue samples from these mice. It became clear
to us that a large percentage of the amyloid plaque-
associated microglia were GFP positive, demonstrating
that many of these cells originate from the blood (Fig-
ures 2A and 2B). Of interest, there is also an age-associ-
ated increase in the amount of infiltrating cells up to the
age of 6 months, whereas their number slightly de-
creased around 9 months of age. We thus quantitatively
measured the amount of plaques present in the hippo-
campus and cortex of these animals, along with their
size and the amount of GFP-positive microglia associ-
ated with the amyloid deposits (Figure 2C). The values
obtained for the number of plaques in the combined
sample areas of each animal were 9.4 6 2.1 (number
of plaques 6 SEM), 6.0 6 2.2, 48.4 6 3.3, and 91.0 6
25.0 plaques for 4 (n = 5), 5 (n = 5), 6 (n = 5), and 9 (n = 2)
month-old mice, respectively. One-way ANOVA analysis
showed a statistical difference between the groups
(f(3,13) = 36.97, p < 0.001), demonstrating that the number
of plaques significantly increased with the age of the an-
imal. A similar phenomenon was observed regarding the
size of the plaques, which had mean areas of 124.4 6
5.4 mm2 (mean area 6 SEM), 152.5 6 20.0 mm2, 192.8 6
16.1 mm2, and 389.2 6 7.8 mm2 in the same age groups,
respectively (f(3,13) = 33.49, p < 0.001). Moreover, we
found that plaques present in 4- and 5-month-old mice
had 0.20 6 0.10 (number of microglia 6 SEM) and
0.126 0.10 plaque-associated GFP+ microglia, whereas
the number significantly increased to 0.94 6 0.18 (p <
0.01) at 6 months of age. Interestingly, the amount of
GFP-positive microglial cells associated to the amyloid
plaques slightly diminished after 9 months of age (0.67 6
0.17), although the difference with the other age groups
was not statistically significant. These data demonstrate
that blood-derived cells infiltrate the brain and migrate
toward amyloid plaques throughout the development
of the disease and that blood-derived microglial migra-
tion toward the amyloid deposits generally seems to oc-
cur after the plaques have achieved a certain size rather
than prior to their formation.
b-Amyloid Peptides Recruit and Activate
Blood-Derived Microglial Cells
The signal that triggers the infiltration of blood-derived
microglia in this model of AD has yet to be unravelled.
Moreover, the ability of different b-amyloid isoforms to
specifically recruit and activate microglial cells in vivo
is still under debate. We thus generated chimeric mice
by transplanting GFP-expressing bone marrow cells
into irradiated wild-type mice. Three months later, we in-
jected 1 ml of either saline, b-amyloid-31, b-amyloid-40,
b-amyloid-42, or b-amyloid-57 (1 mg/mL for each peptide)
directly into the hippocampus of these animals. The an-
imals were sacrificed 3–7 days following the injection,
and cross-sections of the hippocampus were examined
for the presence of GFP-positive cells. As shown in
Figure 3A, b-amyloid-40 and b-amyloid-42 isoforms
were able to provoke the infiltration of GFP-positivecells even in areas distal to the injection site. These re-
sults suggest that bone marrow-derived microglia are
specifically attracted to the b-amyloid-40/42 isoforms.
We next tested whether microglia were immunologi-
cally activated by b-amyloid-42. To achieve this goal,
we injected b-amyloid-42 into the hippocampus of
wild-type CD1 mice. Over the course of 72 hr after the in-
jection, we studied the expression levels of many genes
that are normally induced during an innate immune
response, such as TLR2, TNF-a, IL-1b, and MCP-1 (Fig-
ures 3B and 3C). We found the expression of TLR2,
IL-1b, and MCP-1 mRNAs to be greatly increased follow-
ing b-amyloid-42 treatment when compared to their sa-
line-treated littermates. Conversely, the hybridization
signal for TNF-a remained undetectable in the brain of
acutely treated mice throughout the 3 day period after
the injection, suggesting that b-amyloid-42 does not
elicit a typical innate immune response. Taken together,
these data demonstrate that b-amyloid peptides com-
monly found in AD can recruit blood-derived microglia
and induce an innate immune response in vivo, although
this process does not involve the inflammatory molecule
TNF-a.
We next determined whether a similar immune reac-
tion takes place in the brains of APPSwe/PS1 double-mu-
tant transgenic mice. We thus examined whether the
mRNA expression of the same genes in brain tissue sec-
tions of 4- to 9-month-old APPSwe/PS1 mice was higher
than in WT animals and whether it colocalized with am-
yloid plaques (Figures 4A and 4B). We found that TLR2-
and IL-1b-expressing cells were localized in the vicinity
of amyloid plaques and that their expression levels in-
creased proportionally with the age of the animals,
whereas the signal for TNF-a mRNA was not detectable
in the CNS at all ages. MCP-1 expression in transgenic
versus WT mice was comparable until the age of 6
months, whereas it greatly increased in the brains of 9-
month-old APPSwe/PS1 animals. Taken together, our
data demonstrate that a similar and specific immune ac-
tivity occurs in response to exogenous b-amyloid-42 ad-
ministration and endogenous b-amyloid deposits.
Blood-Derived Microglia Reduce Amyloid Deposits
To this point, we have shown that many bone marrow-
derived cells infiltrate the brain and are greatly attracted
to b-amyloid deposits. However, the role of these cells in
the development of senile plaques remains unclear. To
establish whether blood-derived microglia are beneficial
or detrimental to the development of AD, we crossed the
APPSwe/PS1 double-mutant transgenic mice with a new
line of transgenic animals that express a mutant thymi-
dine kinase (TK) protein under the control of the
CD11b promoter. When treated with ganciclovir, all cells
expressing the TK protein (those of monocytic lineage
only) are eliminated when they undergo cellular division.
However, these animals no longer produce macro-
phages, which are essential for the enucleation of red
blood cells, and thus our mice died from anemia when
treated with ganciclovir i.p. for a period of 10 days. Be-
cause we hypothesized that a longer treatment would
be required to have a significant effect on amyloid
plaque formation, we were compelled to deliver the drug
by other means. We thus chose to deliver the drug di-
rectly into the CNS by installing a chronic in-dwelling
Neuron
492Figure 2. Microglia of Bone Marrow Origin Migrate toward Endogenous b-Amyloid
(A and B) Brain sections of 5-, 6-, and 9-month-old APPSwe/PS1 mice harboring GFP-expressing cells in their bloodstream were immunohisto-
chemically stained to reveal amyloid plaques (b-42 antibody), GFP-positive cells (GFP), and microglia (iba1 antibody). A large portion of plaque-
associated microglia expressed GFP, indicating that they originated from bone-marrow stem cells. In (B), colors were optimized to better visu-
alize GFP and iba1 colocalization (white background Merge). Scale bars represent 100 mm and 25 mm in (A) and (B), respectively. (C) The number
and size of amyloid plaques as well as the number of plaque-associated GFP-positive microglial cells in 4-, 5-, 6-, and 9-month-old APPSwe/PS1
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493Figure 3. Exogenous b-Amyloid Induces the
Infiltration of Blood-Derived Microglia into
the CNS and Induces an Immune Response
(A) Four different b-amyloid isoforms (b-31, b-
40, b-42, and b-57) or saline (not shown) were
injected into the hippocampus of GFP-chi-
meric mice. Seven days later, GFP-positive
microglia were found throughout the hippo-
campus of b-40- and b-42-treated animals,
even in areas much distal to the injection
site. Bone-derived microglia did not migrate
into the CNS in response to the b-31 and b-
57 isoforms. Scale bar represents 200 mm.
(B) Saline or b-42 was injected in the same
hippocampal area of CD1 mice, and mRNA
expression of TLR2, IL-1, MCP-1 and TNF-
awas visualized by in situ hybridization at dif-
ferent time points. The expression of TLR2,
IL-1, and MCP-1 were found to be increased
following acute b-42 treatment in areas distal
to the injection site. Scale bar represents 250
mm. Photographs in (A) and (B) represent the
general response observed in each group. (C)
Qualitative mRNA expression analysis of the
same four genes demonstrates that IL-1b,
MCP-1, and TLR2 are upregulated between
6 and 72 hr post-b-42 treatment, whereas
TNF-a transcript remained comparable to
background levels.cannula into the right lateral ventricle of 15- to 24-week-
old APPSwe/PS1 mice and connecting the cannula to an
Alzet osmotic mini-pump that delivered the solution
over a period of 28 days. With this method, we ensured
that monocytes in the vicinity of the brain would be ex-
posed to ganciclovir and eliminated prior to their differ-entiation into microglia (also see Figure S1), while sys-
temic macrophages remain intact. In this regard, mice
survived and did not show any particular signs of sick-
ness during the chronic i.c.v. ganciclovir infusion.
Cross-sections of the brains were immunohisto-
chemically stained for amyloid deposits and microglialmice were quantitatively analyzed, and the means for each group are presented in these graphs. Error bars represent standard error of means.
Three asterisks denote significant difference (p < 0.05) with all three other age groups, whereas the group with two asterisks is different from 4
and 5 month groups.
Neuron
494Figure 4. Endogenous b-Amyloid also Activates Immune Cells
(A and B) mRNA expression of IL-1b, MCP-1, TLR2, and TNF-a was observed at different stages of plaque formation. (A) Dark (first and third
columns) and bright (second column) field photomicrographs at low magnification (first column) or high magnification (second and third col-
umns) are representative of general mRNA expression found in all animals of their respective age groups. (B) The table corresponds to a qual-
itative analysis of the expression of each gene at 4, 5, 6, and 9 months of age. Similarly to exogenous b-amyloid-42, the endogenous amyloid
protein induces the expression of IL-1b, MCP-1, and TLR2 but not TNF-a. Note that MCP-1 expression was only increased in animals older
than 6 months. Scale bars represent 100 mm.cells (Figure 5A). We next quantified the number and size
of the amyloid plaques as well as the number of plaque-
associated microglia in saline- versus ganciclovir-
treated animals (Figure 5B). As expected, the number
of microglial cells in contact with amyloid deposits
were not different between saline and ganciclovir
groups (f(2,27) = 0.371, p = 0.694). However, the number
of plaques in saline-treated animals were on average
in the order of 23.3 6 13.6 (n = 3), 30.0 6 16.7 (n = 2),
and 16.7 6 13.6 (n = 3) in 4-, 5-, and 6-month-old ani-
mals, respectively. In animals treated with ganciclovir,
there were 19.7 6 7.5 (n = 10), 39.7 6 7.9 (n = 8), and
69.8 6 9.6 (n = 6) plaques in 4-, 5-, and 6-month old an-
imal groups, respectively. A two-way ANOVA suggestedthat a slight interaction between saline and ganciclovir
groups (f(2,27) = 3.286, p = 0.053) was present. After
post-hoc considerations (Bonferroni t test) while assum-
ing interaction between groups, the number of plaques
in saline and ganciclovir treatments in the 6 month group
were significantly different (p = 0.004). The mean areas
of plaques in saline-treated animals were 264.0 6
38.0 mm2 (n = 3), 301.1 6 46.6 mm2 (n = 2), and 163.2 6
38.0 mm2 (n = 3) in 4-, 5-, and 6-month-old groups, re-
spectively, whereas in ganciclovir-treated groups the
mean areas of plaques were 178.1 6 20.8 mm2 (n = 10),
262.2 6 22.0 mm2 (n = 8), and 302.0 6 26.9 mm2 (n = 6)
in the same respective age groups. The two-way ANOVA
indicates a statistically significant interaction between
Blood-Derived Microglia in AD
495Figure 5. Bone Marrow-Derived Microglia Eliminate Amyloid Deposits In Vivo
Saline or ganciclovir was administered to APP-TK mice via an Alzet osmotic mini-pump attached to an indwelling cannula inserted into the right
lateral ventricle for 28 days. (A) Tissues were then stained to reveal amyloid plaques (Congo red), microglia (iba1 antibody) and nuclei (DAPI).
Pictures indicate the general response seen in two different 6-month-old treated animals. (B) Stereological quantitative analysis of the number
and size of plaques found in the cortex and hippocampus. The asterisks denote significant difference with the age-matched saline group. Error
bars represent SEM. (C and D) Visual observations and qualitative analysis of gene expression reveals that IL-1b and TLR2 mRNAs were down-
regulated following ganciclovir treatments, whereas MCP-1 expression was upregulated and TNF-a remained at constitutive levels. Scale bars in
(A) and (C) represent 200 mm.saline- and ganciclovir-treated groups (f(2,27) = 6.688, p =
0.004). Bonferroni post-hoc tests demonstrated that the
average size of plaques in saline and ganciclovir groups
was significantly different only in 6-month-old animals
(p = 0.006). In conclusion, these data suggest that
blood-derived microglia play an important role in reduc-
ing the number and the size of amyloid plaques.
To verify that our treatment method had an effect on
the immune response in these animals, we examinedthe expression levels of TLR2, IL-1b, MCP-1, and TNF-a
by in situ hybridization. We found that IL-1b and TLR2
levels were lower in ganciclovir-treated animals com-
pared to the saline-treated mice at all ages, whereas
MCP-1 expression was more prevalent in the animals
that received the drug (Figures 5C and 5D). On the other
hand, TNF-a expression was still undetectable after gan-
ciclovir treatment. These data suggest that our delivery
method was effective at inhibiting a large part of the
Neuron
496Figure 6. Microglia of Bone Marrow Origin
Are Able to Clear b-Amyloid by Phagocytosis
(A) Six-month-old APPSwe/PS1 tissues were
immunohistochemically stained to reveal b-
amyloid, lysosomes (LAMP-2), bone mar-
row-derived cells (GFP), and microglia (iba1).
As seen in the merged photographs, b-amy-
loid colocalizes with lysosomes in GFP-posi-
tive microglia in vivo. Scale bar represents
10 mm. (B) BV2 microglial cells were treated
with Cy3-conjugated b-amyloid1-42 peptide
and examined by confocal microscopy. It is
evident that the b-amyloid peptide (red) was
present inside the cell (white membrane), as
demonstrated by the different planes of
view. These data confirm that microglia are
able to phagocytose b-amyloid. Scale bar
represents 5 mm.immune response normally associated with amyloid pla-
ques, and this was most likely accomplished by prevent-
ing the infiltration of blood-derived microglia.
Phagocytosis of b-Amyloid by Blood-Derived
Microglial Cells
While analyzing the different Congo red-stained tissues
that were used in these studies, we often observed small
b-amyloid deposits inside many microglial cells (see
Movie S2). This initial result was confirmed with anti-b-
amyloid-42 antibody-stained tissues that were ob-
served by confocal microscopy. After reconstructing
the images with 3D software, it became clear to us that
small amyloid deposits were specifically detected within
subcellular compartments of microglial cells. We thus
tested the hypothesis that microglia were proper phago-
cytes for b-amyloid and performed multiple staining with
the use of antibodies directed against either b-amyloid-
42, LAMP2, or iba1 in brain tissues from 6-month-old ir-
radiated and GFP-transplanted mice. As depicted by
Figure 6A, b-amyloid-42 and LAMP2 staining were colo-
calized within GFP-positive microglial cells in vivo. This
demonstrates that blood-derived microglia are attempt-
ing to clear the amyloid deposits by phagocytosis in
vivo. To further confirm these results, cultured microglial
cells were treated with b-amyloid-42 and subsequently
observed by confocal microscopy. Exogenous Cy3-
conjugated b-amyloid was found to be localized insidethe cultured microglia (Figure 6B), further supporting
our in vivo observations. Therefore, microglia can clear
b-amyloid by phagocytosis both in vivo and in vitro.
Discussion
It is generally accepted that the immune system is in-
volved in the etiology of Alzheimer’s disease. This idea
comes from many reports demonstrating that amyloid
plaques are often surrounded by microglial cells (Dick-
son et al., 1988; Haga et al., 1989; Itagaki et al., 1989;
Perlmutter et al., 1992; Sheng et al., 1997; Frautschy
et al., 1998; Wegiel et al., 2001, 2003, 2004) and the
fact that cultured microglial cells react to b-amyloid by
producing high levels of inflammatory cytokines, such
as IL-1b, TNF-a, and IL-6, among others (Kim and de Vel-
lis, 2005; Walker and Lue, 2005). However, much less
data have been obtained regarding the reactivity of mi-
croglia to b-amyloid in vivo. In fact, due to the in vivo
data published to date, microglial cells have often
been thought to be unable to penetrate the core of am-
yloid plaques (Wegiel et al., 2001, 2003, 2004). These
data and the failure to demonstrate that microglial cells
are able to phagocytose b-amyloid have led to the
assumption that the brain’s resident macrophages pro-
mote the development of the disease because they pro-
duce cytotoxic elements and are unable to clear the b-
amyloid deposits. On the other hand, few studies have
Blood-Derived Microglia in AD
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be beneficial to the organism because it reduces the
amount of amyloid deposition (Rogers et al., 2002;
Malm et al., 2005). Moreover, it has been recently pub-
lished that NSAIDs delay the progression of AD (Stewart
et al., 1997; Anthony et al., 2000; in t’ Veld et al., 2001; Yip
et al., 2005), whereas other studies demonstrate that
NSAID treatments increase the amount of b-amyloid
found in the brain. Therefore, the goal of the present
study was to determine the nature of the role that micro-
glia play in the development of Alzheimer’s disease.
We have recently shown that circulating monocytes
are able to infiltrate the CNS parenchyma and differenti-
ate into microglial cells (Simard and Rivest, 2004a). It
has also been demonstrated that these cells are prefer-
entially attracted to damaged areas of the brain (Tzeng
and Wu, 1999; Kaur et al., 2001; Priller et al., 2001). Inter-
estingly, many reports suggest that activated microglia
promote neuroprotection rather than neurodegenera-
tion (Arnett et al., 2001; Mason et al., 2001; Simard and
Rivest, 2004b). We thus hypothesized that most of the
microglial cells found closely associated with amyloid
plaques are newly differentiated blood-derived micro-
glia and that they serve to slow the progression of AD
by removing the b-amyloid found in senile plaques. We
first compared the properties of amyloid plaques and
associated microglial cells in APPSwe/PS1 mice with
those of the well-established single-mutant line
(APPSwe) and found that they were both very similar in
all aspects except that the double-transgenic line devel-
oped plaques at a younger age. Amyloid deposits in
these animals are similar to those found in human sub-
jects with Alzheimer’s disease; therefore, they are a suit-
able animal model to study this aspect of the disease.
We next asked whether a portion or all of these pla-
que-associated microglia were blood-derived cells.
We created chimeric mice by irradiating APPSwe/PS1
animals and transplanting GFP-expressing bone mar-
row cells into their bloodstreams. When tissue sections
were stained with either Congo red or anti-b-amyloid-42
antibody, it became clear to us that many of the micro-
glia that are in contact with amyloid deposits are indeed
of bone marrow origin. Quantitative analyses of the tis-
sues at different ages demonstrated that the infiltration
of these cells occurs mostly after the age of 5 months,
which is after the onset of the disease, as plaque forma-
tion is already taking place. Prior to this age, the vast
majority of plaque-associated microglia are resident pa-
renchymal cells.
According to previous studies, b-amyloid-40/42 are
the predominant and most toxic forms in amyloid pla-
ques (Nussbaum and Ellis, 2003). We thus tested the
ability of different b-amyloid isoforms to attract blood-
derived cells. We found that only the b-amyloid-40/42
isoforms were able to cause the infiltration of blood-de-
rived microglia. Moreover, b-amyloid-42 was able to in-
duce the expression of inflammatory genes such as
TLR2, IL-1b, and MCP-1, whereas the 31 and 57 amino
acid b-amyloid isoforms did not have an effect. The pro-
teins were injected shortly after their solubilization; thus
they were likely in monomeric forms, possibly with a per-
centage of the protein already forming fibrils. However,
the physical state of the protein is likely modified once
it is in an in vivo environment. Consequently, our studycannot differentiate between the effects of the different
physical states of b-amyloid. We then looked at the ex-
pression levels of inflammatory genes in our transgenic
animals. Interestingly, MCP-1 expression was not de-
tected in significant levels until the age of 9 months in
APP695/PS1 animals. As it seems that blood-derived
microglia are less abundant in 9-month-old animals, it
is tempting to propose that cells in the brains of older
mice are trying to compensate for the diminished infiltra-
tion by substantially increasing the mRNA expression of
this chemokine.
We also found that TLR2 and IL-1b were induced by
cells in the vicinity of the amyloid plaques in the
APPSwe/PS1 model, which supports gene expression
patterns observed in human studies (Kim and de Vellis,
2005; Walker and Lue, 2005). Though TNF-a expression
is increased in cultured microglial cells stimulated with
b-amyloid (Kim and de Vellis, 2005), this cytokine tran-
script was not upregulated in our transgenic animals
or after b-amyloid injections in wild-type mice. Indeed,
the immune response in these animals is not the typical
inflammatory response that is observed in many other
models of neurodegeneration or acute neurotoxicity. It
therefore seems unlikely that inflammation is the direct
cause of neuronal dysfunction in this model of AD. The
precise role of IL-1b in the development of the disease
is still unknown; however, it is quite likely that IL-1b
acts as a signal to induce phagocytosis of b-amyloid
by microglial cells. If this were truly the case, one would
propose that blood-derived microglia were beneficial to
the diseased CNS.
In order to test this hypothesis, we infused ganciclovir
for 28 days into the lateral ventricles of APPSwe/PS1 an-
imals that were crossed with transgenic animals harbor-
ing the TK gene under the control of the CD11b pro-
moter. The drug had to be delivered locally, because
animals submitted to daily systemic injections of ganci-
clovir die after only 10 days of treatment. Nonetheless,
undifferentiated monocytes were exposed to the drug
with our delivery method, and because they undergo
cell-cycle division prior to infiltrating the plaques, these
cells would be eliminated before becoming fully differ-
entiated microglia. To confirm the efficiency of our treat-
ment, we immunohistochemically stained tissues from
our ganciclovir- and saline-treated animals for MHC-II
protein and observed that this protein was only detected
near plaques of saline-treated animals (Figure S1). Only
newly differentiated bone marrow-derived microglia ex-
press components required for antigen presentation (Si-
mard and Rivest, 2004a), suggesting that ganciclovir
treatment effectively blocked the infiltration of blood-
derived cells. Moreover, our treatment method partially
inhibited the increased IL-1b and TLR2 expression that
normally accompanies the disease, whereas MCP-1 ex-
pression was higher in ganciclovir-treated animals. The
latter finding suggests that resident cells in the brains of
these animals were attempting to compensate for the
lack of infiltration by increasing the expression of the
chemoattractant molecule. Finally, two different para-
digms of CNS trauma (stab injury and hypoglossal nerve
axotomy) demonstrated that treatment of CD11b-TK
mice with ganciclovir results in a robust reduction in
the quantity of proliferating microglia and the microglial
cell population in these mice can also gradually recover
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ganciclovir treatment (Gowing et al., 2006).We are there-
fore confident that our method of drug delivery success-
fully prevented the infiltration of new microglial cells ad-
jacent and within the plaques.
Another group has recently created CD11b/TK ani-
mals and utilized these mice to study the role of micro-
glia in experimental autoimmune encephalomyelitis
(Heppner et al., 2005). These authors presented the
CD11b/TK mice as a model of microglial paralysis rather
than inhibition of proliferating microglia. To the contrary,
our mouse model does not have inhibition of parenchy-
mal microglia, but rather has a depletion of newly differ-
entiated bone marrow-derived microglia. This was de-
termined by various approaches, and the most reliable
one was the injection of lipopolysaccharide (LPS) di-
rectly into the CNS of ganciclovir- and saline-treated
TK animals (see Figure S2) to trigger proinflammatory
signaling in microglia (Nadeau and Rivest, 2002). These
data clearly show that proinflammatory signaling is
functional in our CD11b/TK mice, and thus only newly
differentiated microglia are being targeted by the drug.
This rapid inflammatory reaction to LPS is only taking
place in resident microglial cells, not in infiltrating mono-
cytes. We can therefore conclude that we have specifi-
cally inhibited the recruitment of blood-derived micro-
glia and not the activation of resident microglia.
Quantitative analysis of our tissues showed that gan-
ciclovir treatment increased the size and number of am-
yloid plaques when compared to their age-matched sa-
line counterparts. Moreover, the levels of cytokine
expression detected in animals that received the drug
were lower than animals treated with saline; therefore,
the drug was able to attenuate the immune response
normally seen in APPSwe/PS1 animals. The facts that
GFP+ cells were more prevalent in 6-month-old animals
and that ganciclovir treatment only had an effect at this
specific age further demonstrate that our treatment
method was effective at blocking the infiltration of
monocytic cells. These data and those showing that res-
ident microglial cells were still present in the vicinity of
the plaques of ganciclovir-treated animals suggest
that newly differentiated microglial cells originating
from the blood are able to remove b-amyloid from the
extracellular environment, whereas resident microglia
are ineffective at b-amyloid phagocytosis. Interestingly,
the number and size of amyloid plaques seemed to be
lower in 6-month-old saline-treated animals, whereas
expression levels of IL-1b and TLR2 seemed higher
when compared to untreated transgenic animals (please
compare Figure 2C with Figure 5C, and Figure 4C with
Figure 5D). These results have a few implications: first,
an increased immune response in the brain reduces
the amounts of b-amyloid deposits, and second, remov-
ing the presence of blood-derived microglial cells com-
pletely blocks the positive effects of inflammation in
these brains. The first implication is supported by previ-
ous studies showing that microglial cell activation by
LPS lowers the b-amyloid burden in the hippocampus
(Malm et al., 2005). However, here we show that blood-
derived microglial cells are able to clear b-amyloid de-
posits or to prevent their formation.
It has previously been suggested that microglial cells
are unable to phagocytose b-amyloid in vivo (Walker andLue, 2005). Conversely, we observed in our initial find-
ings that microglial cell ramifications often seem to pen-
etrate toward the center of the amyloid deposits with the
single-mutant transgenic line (APPSwe mutation). Fur-
thermore, Congo red staining was often seen within cy-
toplasmic microglial cell structures (see Movie S2).
These data suggest that microglial cells may indeed be
able to clear b-amyloid deposits by phagocytosis. We
found that b-amyloid-42 and lysosomes colocalized in
nearly all GFP-positive microglia, whereas the majority
non-GFP microglia did not have intracellular b-amy-
loid-42. This finding and the fact that large plaques in
the later stages of the disease, such as those often ob-
tained from human samples, contain fewer blood-de-
rived microglia may explain reports of human studies
demonstrating a lack of b-amyloid phagocytosis by mi-
croglial cells (Walker and Lue, 2005).
Some studies have proposed that microglia contrib-
ute to the deposition of b-amyloid by concentrating the
soluble protein and releasing it into the cellular environ-
ment once it dies by apoptosis or by producing the pro-
tein itself (Wegiel et al., 2001, 2003, 2004), though these
studies base their conclusions on many assumptions.
However, it must be noted that these studies do not dis-
tinguish between resident and blood-derived microglial
cells. It is possible that one of these cells favors plaque
formation, while the other serves to prevent or clear am-
yloid deposits. Three major results provided by the pres-
ent study support this hypothesis. First, every plaque
observed in our study was accompanied by at least
one type of microglial cell, though our analyses demon-
strate that blood-derived microglia are only present in
senile plaques that have attained a certain size after
a certain age, since many of the smaller plaques in the
4- to 5-month-old animals were not associated with
GFP+ cells. This suggests that resident microglia are
present at the onset of plaque formation and hence
may play a role in this process, whereas blood-derived
microglia appear at later stages of the disease and
may therefore be attempting to clear the senile plaques.
Second, the amount of blood-derived microglia in con-
tact with amyloid plaques seems to slightly decrease,
while resident microglia are found in greater numbers
at 9 months of age, which coincides with the time
when the most significant increase in amyloid deposi-
tion occurs. Finally, plaque size and number were
much lower in animals treated with saline solution,
whereas inhibition of bone marrow-derived microglia
substantially increased the presence of amyloid
plaques.
In conclusion, we demonstrate that blood-derived mi-
croglial cells that are associated with amyloid plaques
are able to prevent the formation or eliminate the pres-
ence of amyloid deposits in mice that develop the major
hallmark of AD. We also show that these cells are specif-
ically attracted to b-amyloid in vivo and that they partic-
ipate in the elimination of this protein by phagocytosis.
The fact that newly recruited microglia are more efficient
immune cells compared to their resident counterparts is
clearly a beneficial mechanism in restricting disease
progression. A novel strategy to target and improve
such a process toward b-amyloid deposits could lead
to the elimination of toxic senile plaques by bone mar-
row stem cells in AD.
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Animals
Transgenic animals harboring the human presenelin 1 (A246E vari-
ant) and a chimeric mouse/human b-amyloid precursor protein
(APPSwe) were obtained from The Jackson Laboratory [B6C3-
Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J; The Jackson Laboratory, Bar
harbor, ME]. Hemizygous transgenic mice expressing green fluores-
cent protein (GFP) under control of the chicken b-actin promoter and
cytomegalovirus enhancer were initially obtained from the same
vendor. Transgenic animals that express the thymidine kinase (TK)
protein specifically in cells of monocytic lineage were generated
with the use of standard molecular biology techniques. Briefly,
HSV-1 TKmt-30 (TKmt-30) DNA constructs under the control of the
human CD11b promoter were created. The CD11b promoter region
was amplified by PCR from human genomic DNA using Vent DNA
polymerase (NEB, Beverly, MA). The following PCR conditions
were used: 94ºC for 4 min, 34 cycles (94ºC for 30 s, 62ºC for 30 s.,
72ºC for 2 min) 72ºC for 10 min. The 50 primer (50-CCCAAG
CTTGGGGGTTCAAGTGATTCTGCTGC-30) hybridized z 1.7 kb up-
stream from the main initiation site. The 30 primer (30-CGGGATCCC
GAGAAACCTGGAGGTG AACC-50) hybridized 15 bases upstream
from the initiation ATG. HindIII and BamHI restriction sites were
added to the 50 and 30 primers, respectively, for orientation cloning.
The PCR products were then subcloned in pBluescript SK+ (Strata-
gene, La Jolla, CA). The Pet23d vector containing TKmt-30 (a gift
from Dr. M. Black, University of Washington) was digested with
NcoI to excise a 1.4 kb fragment containing the coding sequence
of the TKmt-30 gene (1.1 kb). The TKmt-30 gene was cloned into
the BamH1 site of the CD11b pBluescript SK+ vector. A 2.9 kb
DNA HindIII and Xbal fragment containing the fusion CD11b-TKmt-
30 gene was purified using b-agarose (NEB, Beverly, MA) and then
microinjected into one-cell mouse embryos of C57BL/6 genetic
background according to standard procedures (Brinster et al.,
1981).
The genomic integration of the transgene was confirmed by
Southern blot analysis from mouse-tail DNA. An 800 bp TKmt-30
probe was generated by digestion of CD11b- TKmt-30 vector with
EcoRV and BssHII. This probe detected a 1.4 kb band correspond-
ing to the TKmt-30 transgene with digestion of mouse genomic DNA
by NcoI. Once transgenic lines were established, mice were geno-
typed by PCR with TAQ DNA polymerase (Amersham, Piscataway,
NJ) in 17 mM MgCl2 PCR buffer with the following primers: 5
0-
CCCCTGCCATCAACACGCGTCTGC and 50-CGGCGTCGGTCACGG
CATAAGGC (position 12–35 and 412–390, respectively). The PCR
conditions were as follows: 94ºC for 2 min, 34 cycles (94ºC for
30 s, 55ºC for 30 s, 72ºC for 30 s) 72ºC for 10 min.
These animals were then crossed with the APP695/PSEN1 ani-
mals to generate triple-transgenic animals (subsequently named
APP-TK animals). Colonies for each strain were maintained in
a C57BL/6J background. All animals were acclimated to standard
laboratory conditions (14 hr light, 10 hr dark cycle; lights on at
06:00 and off at 20:00 hr) with free access to rodent chow and water.
GFP mice were used as cell donors at 4–6 months of age. All proto-
cols were conducted according to the Canadian Council on Animal
Care guidelines, as administered by the Laval University Animal Wel-
fare Committee.
Irradiation and Bone Marrow Transplantation
A group of APPSwe/PS1 mice were exposed to 10 gray total-body ir-
radiation using a cobalt-60 source (Theratron-780 model, MDS Nor-
dion, Ottawa, ON, Canada). A few hours later, the animals were in-
jected via a tail vein with w5 3 106 bone marrow cells freshly
collected from GFP mice. The cells were aseptically harvested by
flushing femurs with Dulbecco’s PBS containing 2% fetal bovine
serum (DPBS-FBS). The samples were combined, filtered through
a 40 mm nylon mesh, centrifuged, and passed through a 25 ga
needle. Recovered cells were resuspended in DPBS at a concentra-
tion of 5 3 106 viable nucleated cells per 200 ml. Irradiated mice
transplanted with this suspension were housed in autoclaved cages
and treated with antibiotics (0.2 mg trimethoprim and 1 mg sul-
famethoxazole/ml of drinking water given for 7 days before and
2 weeks after irradiation). Animals were sacrificed 2–7 months after
transplantation.Intracerebral Injections
Animals were anesthetized with isofluorane, and the site of injection
was stereotaxically reached (David Kopf Instruments, Tujunga, CA).
For the acute intrahippocampal injections of b-amyloid peptides, the
coordinates from the bregma were +2 mm anteroposterior, 22 mm
lateral, and 22.3 mm dorsoventral. One microliter of solution con-
taining either 0.9% NaCl or recombinant b-amyloid-31 (1 mg/ml;
rPeptide, Athens, GA), b-amyloid-40 (1 mg/ml; Bachem Bioscience
Inc., King of Prussia, PA), b-amyloid-42 (1 mg/ml; Bachem Biosci-
ence Inc.), b-amyloid-57 (1 mg/ml; rPeptide), or lipopolysaccharide
(LPS 2.5 mg/ml; Sigma Aldrich) was delivered over a period of 2
min. All of the b-amyloid injections were performed within a few
hours following solubilization of the drug. The mice then received
a 1 ml dose of Ringer’s lactate (Abbott Laboratories, Saint-Laurent,
Canada) and were housed up to four animals per cage. The animals
were then sacrificed at different time points (6, 12, 24, 72, or 168 hr
postinjection).
For the chronic intracerebroventricular injections of ganciclovir,
the coordinates from the bregma were +0.1 mm anteroposterior,
21 mm lateral, and 23 mm dorsoventral. The guide cannula (Alzet
Brain infusion kit III 1–3 mm, Durect Corporation, Cupertino, CA)
was secured with screws and cranioplastic cement (Cranioplastic
powder, Plastic One Inc., Roanoke, VA; Dentsply repair material,
Dentsply International, York, PA). Approximately 40 hr prior to the
surgeries, the Alzet pumps (0.25 mL/hr, 28 day pumps, Durect Cor-
poration) were filled with either a solution containing 0.9% saline
and 0.04% hydrogen chloride (carrier solution) or a solution contain-
ing 1 mg/ml ganciclovir (Cytovene; RocheDiagnostics, Laval, QC,
Canada) diluted in carrier solution. The pumps were then incubated
in a saline solution at 37ºC until the time of surgery, in order to ensure
that drug delivery initiates immediately after implantation. The ani-
mals were then housed individually and were sacrificed 28 days fol-
lowing the surgery. The pumps were manually tested to verify that
the canula was not blocked and that the drug was delivered through-
out the implantation period.
To collect the brain tissues in all experiments described above,
mice were deeply anesthetized via an i.p. injection of a mixture of
ketamine hydrochloride and xylazine, and then rapidly perfused
transcardially with 0.9% saline, followed by 4% paraformalde-
hyde/3.8% borax in sodium phosphate buffer (pH 9 at 4ºC). Brains
were rapidly removed from the skulls, postfixed overnight, and
then placed in a solution containing 10% sucrose diluted in 4% para-
formaldehyde/3.8% borax buffer (pH 9) overnight at 4ºC. The frozen
brains were mounted on a microtome (Reichert-Jung, Cambridge In-
struments Company, Deerfield, IL), frozen with dry ice, and cut into
25 mm coronal sections from the olfactory bulb to the end of the me-
dulla. The slices were collected in a cold cryoprotectant solution
(0.05 M sodium phosphate buffer, pH 7.3, 30% ethylene glycol,
20% glycerol) and stored at 220ºC.
Immunohistochemistry
Free-floating sections (25 mm thick) were incubated for 30 min in
KPBS containing 4% goat serum, 1% BSA, and 0.4% Triton X-100.
Using the same buffer solution, the sections were then incubated
for 90 min in primary Ab (polyclonal rabbit anti-ionized calcium bind-
ing adaptor molecule 1 [iba1], 1:2000, Wako Chemicals, Richmond,
VA; monoclonal mouse anti-b-amyloid1-42, 1:500, Vector Laborato-
ries, Inc., Burlingame, CA; polyclonal rabbit anti-green fluorescent
protein [GFP], 1:2000, Molecular Probes, Eugene, OR; monoclonal
rat anti-LAMP2 1:500, Developmental Studies Hybridoma Bank, Uni-
versity of Iowa, Iowa City, IA; monoclonal mouse anti-MHC class II I-
Ab 1:500, Cederlane, Hornby, ON, Canada) at room temperature. The
sections were then rinsed four times for 5 min in KPBS, followed by
a 90 min incubation in fluorochrome- or biotin-conjugated goat sec-
ondary Ab (anti-rabbit Alexa-488, 1:1000, Molecular Probes; anti-
rabbit Cy5, 1:1000, Jackson ImmunoResearch Laboratories Inc.,
West Grove, PA; anti-mouse Cy3, 1:500, Jackson ImmunoResearch;
anti-mouse AMCA, 1:500, Jackson ImmunoResearch; anti-mouse
IgM 1:1000, Vector Laboratories, Inc.). Sections were then rinsed
four times for 5 min in KPBS, mounted onto SuperFrost slides (Fisher
Scientific, Nepean, Ontario, Canada), stained with DAPI (23 1024%;
Molecular Probes), and coverslipped with antifade medium com-
posed of 96 mM Tris-Hcl, pH 8.0, 24% glycerol, 9.6% polyvinylalco-
hol, and 2.5% diazabicyclooctane (Sigma). Confocal laser scanning
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the Fluoview SV500 imaging software 4.3 (Olympus America Inc,
Melville, NY). Confocal images were acquired by sequential scan-
ning using a two-frame Kalman filter and a z-separation of 1 mm.
The images were then processed to enhance contrast and sharp-
ness using Adobe Photoshop 7 (Adobe Systems) and were assem-
bled using Adobe Illustrator (Adobe Systems).
In Situ Hybridization
In situ hybridization was performed on every 12th section of the
brain, starting from the end of the olfactory bulb to the end of the cor-
tex, using 35S-labeled cRNA probes as described previously (La-
flamme and Rivest, 1999; Laflamme et al., 2003; Nadeau and Rivest,
2003).
Estimation by Stereology of Both the Size and Number
of the Plaques, and the Number of Infiltrating Microglial
Cells Surrounding the Plaques
All quantitative histological analyses were done by an observer who
was blind to the treatment status of the material. Overall, 17 APP
brains and 32 APP-TK brains were analyzed. Systematically sam-
pled sections (every 12th section through the hippocampus region)
were stained with DAPI for nuclei and Congo red for amyloid plaques
and immunostained for blood-derived microglial cells with GFP an-
tibody. Using a stereotaxic atlas (Paxinos and Franklin, second edi-
tion) as a reference, two slices at21.70 mm and23.08 mm from the
bregma were analyzed for each brain. The Stereo Investigator soft-
ware (Microbrightfield, Colchester, VT) was used both to drive a mo-
torized stage (Ludl, Hawthorne, NY) on a dual optical head Nikon
C80i microscope and to capture real-time images (1600 3 1200
pixels) from samples with a Microfire CCD color camera (Optronics,
Goleta, CA) through a 43 Plan Apochromat objective (NA 0.2) in
brightfield mode. The contours of the cortex and hippocampus
areas were traced as a virtual overlay on the streamed images
with a Cintiq 18S interactive pen display (Wacom, Vancouver, WA).
Thereafter, the software sequentially chose counting frames (670
3 500 mm) every 2000 mm in the x axis and every 1000 mm in the y
axis while moving automatically the motorized stage into the previ-
ously delimited zones in the cortex and the hippocampus. In the se-
lected counting frames, the contour of Congo red-labeled plaques
was traced with the interactive pen display by using Stereo Investi-
gator software; the microscope was at this time set with a 403 Plan
Apochromat objective (NA 0.95) and a triple-band filter set (DAPI/
FITC/TRITC, Chroma Technology, Rockingham, VT) for epifluores-
cence observations in the three channels simultaneously. The num-
ber of labeled cells was estimated by the optical fractionator method
in Stereo Investigator software as follows: GFP-immunoreactive
cells were counted only if their cell body was in contact with the am-
yloid plaque and if their nuclei labeled with DAPI laid within the dis-
sector area did not intersect forbidden lines and came into the focus
as the optical plane moved through the height of the dissector (20
mm). The guard zone thickness was set to 2 mm. Overall, the sum
of the sampling site areas represented around 15% of the total
area of the slice. This method of sampling was tested in a pilot ex-
periment to ensure that the estimation of the number of plaques
was representative of their total number.
Preparation of Cy3-Labeled Amyloid-b
b-amyloid1-42 (Anaspec, San Jose, CA) was dissolved at 1 mg/ml in
50 mM phosphate buffer (pH 7.0–7.3) and conjugated with Cy3
monofunctional dye (Amersham Bioscience, Piscataway, NJ) follow-
ing the manufacturer’s guidelines. Briefly, 5 ml of coupling buffer was
thoroughly mixed to 100 ml of the solution of amyloid peptides, the
resulting solution was then mixed to the vial of Cy3 reactive dye
and incubated 30 min at room temperature with additional mixing
every 10 min. Unconjugated dye was separated from the labeled
peptides by dialysis overnight in a 3.5 K MWCO Slide-A-Lyzer dial-
ysis cassette (Pierce, Rockford, IL). Fluorescent intensity of dialysed
Cy3-labeled Amyloid peptides was measured with a SLM AMINCO
Bowman AB2 spectrofluorimeter (Exc: 550 6 4 nm; Em: 564 6 4
nm; sensitivity: 835 volts, high-voltage enable) and compared to
a nondialysed one (100% of Cy3 dye); only 12.3% of the Cy3 fluores-
cence was remaining after dialysis. Taking into account that a 1-42
amyloid peptide exposed seven free amino groups for conjugation,40% of the amyloid peptides could be fully labeled with Cy3 dye,
suggesting that the dialysis was complete (no more Cy3-reactive
dye than conjugation sites). The solution of Cy3-labeled amyloid
peptide was used later as a fluorescent tracer when mixed with non-
labeled amyloid proteins in cell culture medium.
Cell Culture and Immunocytochemistry
BV2 microglial cells (generously provided by Dr. Luc Vallie`res) were
routinely grown in DMEM (Gibco, Invitrogen, Burlington, ON) supple-
mented with 10% fetal bovine serum (Wisent, St-Bruno, QC), 100
units of penicillin/ml, 100 bg of streptomycin/ml, at pH 7.4 and
37ºC in an H2O-saturated, 5% CO2 atmosphere. Cells were seed at
10000 cells per well in height-chamber glass slides (Lab-Tek, Nalge
Nunc International, Rochester, NY). Two days later, cells were incu-
bated for 1 hr with 25 bg/ml b-amyloid1-42 (Anaspec, San Jose, CA)
and 2.5 mg/ml of Cy3-labeled b-amyloid1-42. Thereafter, cells were
rinsed several times with HBSS and then fixed with 4% formalde-
hyde (pH 7.4) during 15 min at 37ºC. Cells were rinsed three times
with HBSS. Chambers were removed from the slide, and cells
were coverslipped with a polyvinyl alcohol (Sigma-Aldrich) mounting
medium containing 2.5% 1,4-diazabicyclo(2,2,2)-octane (Sigma-Al-
drich) in buffered glycerol (Sigma-Aldrich).
Confocal Laser Scanning Microscopy for Phagocytosis
Experiments
Confocal laser scanning microscopy was performed with a BX-61
microscope equipped with the Fluoview SV500 imaging software
4.3 (Olympus America Inc, Melville, NY), using a 1003 Plan-Apo-
chromat oil-immersion objective (NA 1.35) and a 2–3.53 zoom ratio
in the region of interest. Cy3-labeled amyloid peptide was excited at
543 nm using an argon-He laser (Melles Griot Laser Group [Carlsbad,
CA]) set at 70% of maximum power. Fluorescence emission from
Cy3 dye was recorded by photomultipliers with emission filter preset
within FV500 software (Red pseudocolor; BA: 560–600 nm). Trans-
mission channel was captured in the same time to delineate the
shape of the cells. 0.1 mm confocal z-series were acquired for
each observation area and filtered by three-frame Kalman low-
speed scans. Acquired z-series images were exported in Imaris
Pro Sofware 4.2.0 (Bitplane AG, Zurich, CH).
Tridimensional Reconstructions, Modelings, and Animations
Z-series of the different experiments were imported from the Olym-
pus Fluoview format to the Imaris Pro Software running on a Dell
Precision 650 dual Intel Xeon workstation equipped with 4 GB of
RAM and a PNY Quadro FX3000G graphic accelerator. Image
thresholding and channel pseudocolors were adjusted, and 3D re-
construction was performed in a Surpass Scene as follows: orthog-
onal view of either the maximum intensity projection (MIP) or the
blend projection of the volume of the stacked images were captured,
first, channel by channel, and then all the channels together in the
Surpass module. Pictures were cropped with Adobe Photoshop
CS and thereafter assembled in Adobe Illustrator CS. Modelling of
the objects was performed in perspective view, channel by channel;
while overlaying carefully with 3D rotations the objects from the orig-
inal MIP volume with the new isosurfaces generated by advanced
Gaussian filter/Threshold level settings. Objects were automatically
closed at the border. Light source was set to optimize the 3D render-
ing effects on the textures wrapping the different objects. Anima-
tions were created in two steps. First, movements of the amyloid
plaque in 3D were added as key frames in the animation scenario.
In a second step, several effects, such as MIP background for vol-
ume/blend background for models, zoom in/out, opacity/transpar-
ency of specific channels, yellow selection boxes, clipping planes,
and ortho slicers were added at specific time points to look inside
and around the amyloid plaque and put in evidence the intimate re-
lationships between the plaque and the surrounding microglial cells.
High-resolution movies were exported in the .avi file format and then
heavily compressed with Microsoft Windows Movie Maker.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/49/4/489/DC1/.
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